| Document |
Document Title |
|
WO/2024/063648A1 |
The present invention is directed to a scaffold and a compound for targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts (CAFs). The scaffold comprises a (4-quinoinolyl)glycinyl-2-cyanopyrrolidine scaffold that i...
|
|
WO/2024/056678A1 |
The present invention relates to compounds according to formula (I), which are prodrugs of the psychoactive compound phenethylamine or its derivatives. The prodrugs provided herein exhibit improved pharmacokinetic properties during uptak...
|
|
WO/2023/245040A1 |
Compounds, methods, and compositions for treating or preventing viral infections using flexible nucleosides analogs. The fleximer and reverse fleximer nucleoside analogues having increased flexibility and ability to alter their conformat...
|
|
WO/2023/220219A1 |
The present disclosure features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
|
|
WO/2023/205206A1 |
Provided are compounds useful for the treatment and prevention of infectious diseases. The compound structures are lincosamide analogs modified at the aminooctose (northern) and amino acid (southern) regions. Also provided are methods fo...
|
|
WO/2023/150151A1 |
Disclosed herein are embodiments of compounds that exhibit Crk-like protein inhibition. The compound embodiments can be used to suppress or prevent tumor cell growth, augmenting immune cell response in a subject having, or suspected of h...
|
|
WO/2023/146785A1 |
The present disclosure provides compounds of the formula (III) and their pharmaceutically acceptable salts, and compounds of the formula (IV) and their pharmaceutically acceptable salts, and pharmaceutical compositions comprising these c...
|
|
WO/2023/140186A1 |
The purpose of the present invention is to provide: a photochromic compound having an excellent color fading rate and excellent durability; a naphthol derivative that can become an intermediate for the photochromic compound; and a curabl...
|
|
WO/2023/122778A1 |
Disclosed herein are oxime compounds having the structure of Formula (I'): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein L1, L2, R1, R2, R3, R4, R7, n, and r are as defin...
|
|
WO/2023/116811A1 |
A short peptide compound containing β-aminoketone and the use thereof, and specifically disclosed is a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/096209A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode; and an...
|
|
WO/2023/019351A9 |
Provided is a method of treating a subject with an α-synucleinopathy neurodegenerative disorder, the method comprising administering one or more therapeutic(s) to the subject, a method of treating a subject with a high risk of developin...
|
|
WO/2022/268119A1 |
A sulfoximine compound and a use thereof. Specifically disclosed is a compound represented by the following formula or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/246662A1 |
The present disclosure relates to the technical field of display, and provides an organic compound and a light-emitting device. The structure of the organic compound is as represented by formula 1, formula 2 or formula 3. According to th...
|
|
WO/2022/221194A1 |
Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
|
|
WO/2022/204683A1 |
Disclosed herein are quinazolinyl compounds, compositions, and methods of use thereof. The compounds may be used in the treatment of kinase-related disorders (including cancer, autoimmune disease, and Duchenne muscular dystrophy).
|
|
WO/2022/116714A1 |
Provided in the present application are a compound and the medical use thereof for novel coronavirus pneumonia, which belongs to the technical field of pharmaceuticals. The compound is a compound represented by formula I or formula II, o...
|
|
WO/2022/107724A1 |
The present invention provides: a novel azetidinone derivative having excellent herbicidal activity, or a salt thereof; an herbicide containing the same as an active ingredient; and a production intermediate. Provided are: an azetidinone...
|
|
WO/2022/015624A1 |
This present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I) and ph...
|
|
WO/2021/248022A1 |
The present disclosure relates to a pharmaceutical composition, such as a dry powder inhalation formulation or an injectable formulation, comprising a mixture of an antiviral agent and a mast cell stabilizer. The present disclosure relat...
|
|
WO/2021/230681A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2021/206305A1 |
The present invention provides: a compound represented by Chemical Formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electr...
|
|
WO/2021/160132A1 |
Disclosed in the present invention are a heterocyclic compound, a preparation method therefor and use thereof. The present invention provides a heterocyclic compound as shown in formula I or a pharmaceutically acceptable salt thereof. Th...
|
|
WO/2021/138391A1 |
Disclosed herein are indazole compounds and methods of treating diseases and/or conditions (e.g., cancer) with the indazole compounds disclosed herein.
|
|
WO/2021/128764A1 |
The present application relates to the technical field of organic materials, and provides a nitrogen-containing compound, an electronic element, and an electronic device. The structure of the nitrogen-containing compound is as shown in a...
|
|
WO/2021/123051A1 |
The present disclosure relates to substituted thiophene carboxamides derivatives of formula (I) adn (II), their use for controlling phytopathogenic microorganisms and compositions comprising thereof.
|
|
WO/2021/120992A1 |
The invention belongs to the field of chemistry. Specifically, disclosed is triazole derivatives, and an application of the derivatives in plant growth regulation and fungicides. The triazole derivatives are compounds as shown in general...
|
|
WO/2021/120838A1 |
Disclosed is an organic compound, an electronic device containing the organic compound, and an electronic apparatus having the electronic device. A main structure of the organic compound is a fused heterocyclic aromatic group containing ...
|
|
WO/2021/080334A1 |
The present invention relates to a compound for an organic electronic element, an organic electronic element using same, and an electronic device comprising the organic electronic element. According to the present invention, an organic e...
|
|
WO/2021/074414A1 |
The present invention relates to compounds with the ability to stimulate/induce ubiquitination of a target protein/target proteins. The compounds of the present invention may stimulate/induce ubiquitination of a target protein/target pro...
|
|
WO/2021/067521A1 |
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...
|
|
WO/2021/060723A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic layer placed between the first and second electrodes; and an ele...
|
|
WO/2021/051231A1 |
Disclosed is a new class of photo-responsive coordination compounds with at least one photochromic unit on a coordinating ligand. The photo-responsive coordination compounds are shown to be capable of acting as electroactive materials fo...
|
|
WO/2021/028521A1 |
A process to reduce the odor of compounds with at least one five-membered cyclic monothiocarbonate group, shortly referred to as monothiocarbonate compounds, is provided, wherein the monothiocarbonate compounds are in a liquid phase and ...
|
|
WO/2021/024925A1 |
The present invention aims to provide: a chemically amplified positive photosensitive resin composition that contains an acid generator having excellent solvent solubility and can readily form a resist pattern having excellent mask linea...
|
|
WO/2020/262134A1 |
The present invention addresses the problem of providing a purification method for an actinic ray-sensitive or radiation-sensitive resin composition which can be used to form a pattern in which defects are inhibited. The present inventio...
|
|
WO/2020/229393A1 |
A process for the synthesis of compounds comprising at least one non-cyclic carbonate group is provided, wherein a compound A) comprising at least one five-membered cyclic monothiocarbonate group is reacted with at least one hydroxy grou...
|
|
WO/2020/224396A1 |
Provided in the present invention are a class of compounds inhibiting TDG activity. In particular, provided in the present invention is a compound as shown in formula I and which has a new structure. The small-molecule inhibitor of the p...
|
|
WO/2020/211822A1 |
The present invention relates to a class of bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof, and specifically provides a compound shown in formula (I), or an isotopic compound t...
|
|
WO/2020/202944A1 |
Provided is an active light-sensitive or radiation-sensitive resin composition, etc., that is capable of forming a pattern having an extremely excellent rectangular shape in the cross-section thereof, when forming a pattern having an ext...
|
|
WO/2020/191091A1 |
This invention provides for compounds of the formula wherein the variables are defined herein, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, or salt thereof, compositions comprising these compounds, and method for the treatment...
|
|
WO/2020/165102A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...
|
|
WO/2020/156363A1 |
The present application discloses an immunomodulator, and specifically discloses a compound depicted by formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound provided in the present applicati...
|
|
WO/2020/148423A1 |
Provided is a process for the preparation of a compound comprising at least one cyclic monothiocarbonate group wherein a salt of an acidic compound with at least one acidic hydrogen atom is reacted with a compound of formula (I), wherein...
|
|
WO/2020/138732A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric device comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrode...
|
|
WO/2020/109509A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1, useful as pesticides, and especially fungicides.
|
|
WO/2020/106028A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2020/056090A1 |
Disclosed are compounds of Formulae 1 and 10 including all geometric and stereoisomers, tautomers, N oxides, and salts thereof, wherein E, L, J, A, T, R1, R2a, R2b, X, Y, R6a, R6b and R29 are as defined in the disclosure. Also disclosed ...
|
|
WO/2020/035070A1 |
A 3-aryloxy-3-aryl-propylamine compound or a pharmaceutically acceptable salt of same, or a prodrug of same, and uses thereof. The compound has the structure of formula I. The compound, the pharmaceutically acceptable salt of same, or th...
|
|
WO/2020/023389A1 |
Disclosed herein are polymer conjugates comprising an active agent linked to a polymer, wherein the active agent comprises an inhibitor, antagonist, or inverse agonist of a mediator of a therapeutic target associated with a condition, in...
|
